Oura to acquire medical AI startup Counsel Health for $625M

Oura announced on Tuesday that it has agreed to acquire Counsel Health, an AI-native primary care company, for $625 million, according to TechCrunch. The deal comes weeks after Oura postponed an IPO of up to $2.2 billion indefinitely, citing "uncertainty in the IPO market," TechCrunch reported. The Verge, which covered the announcement alongside Oura's quarterly earnings, reported that Oura expects the deal to close before the end of the year, while TechCrunch put the expected close before the end of 2027. Counsel Health combines a chat-based medical experience with access to licensed physicians. Its service was integrated into the Oura app in June, letting users put questions to Counsel's medical AI and then speak with a physician when needed, all inside the app. The two companies now plan to build across preventative care, acute care, and specialty and chronic care. The Verge reported that the stated focus covers preventative care, acute care for episodic health concerns, and specialty and chronic care for areas such as reproductive and cardiometabolic health.

What Oura is actually buying

The strategic logic is less about adding a chatbot than about closing the loop between measurement and action. Oura chief executive Tom Hale said in a press release that "Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals." Counsel chief executive Muthu Alagappan framed the fit around clinical caution, saying "we've built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions," and that Oura's data gives clinicians "objective context, trended biometrics, and member engagement to deliver more informed care." Both quotations were carried in TechCrunch's report. Counsel is not a large organisation. TechCrunch reported that it raised a $25 million Series A a year ago, led by Andreessen Horowitz and GV, and that PitchBook estimates total fundraising of $36 million. The Verge, citing Bloomberg, reported that Counsel's network of on-demand physicians is currently "made up of about 50 people," and that Alagappan plans to expand it. Counsel's 70 employees will join Oura, with Alagappan becoming Oura's chief clinical AI officer, according to both outlets.

The commercial backdrop

The acquisition lands against strong numbers. TechCrunch reported that Oura's revenue grew 153% year over year to $533 million for the quarter ended 30 September, and that the company generated approximately $1.75 billion in revenue for its fiscal year 2026, growth of 92%. Oura reached an $11 billion valuation after a $900 million late-stage funding round in October 2025, TechCrunch reported. Against that, the postponed listing suggests the company is choosing to build rather than test public markets on uncertain terms. Competitive pressure is part of the context TechCrunch sets out: Oura has largely dominated the smart ring market for years, but rivals such as RingConn and Ultrahuman are emerging, pushing the company to keep innovating. Buying a clinical layer is one way to differentiate a hardware category where sensor specifications tend to converge.

Who is affected

The immediate beneficiaries are Oura's existing members, who gain a more direct route from ring data to medical advice, and Counsel's enterprise customers. Oura said Counsel will continue serving existing and new enterprise partners, with the goal of expanding its AI-native care model beyond Oura's membership. The Verge reported that this includes "health plans, health systems, consumer health organizations, and employers." That matters commercially: it means Oura is not simply bolting a service onto its own subscriber base but acquiring a business-to-business channel into payers and providers. For founders and investors in regulated health AI, the deal is a pricing reference. A company with roughly $36 million in total funding, a physician network of about 50 and 70 staff has been valued at $625 million by a strategic buyer with an $11 billion valuation. That is a strong multiple, and it reflects the scarcity of assets that combine clinical oversight with consumer-grade distribution rather than pure model capability.

Risks and unknowns

The sources leave several questions open. Neither report sets out how much of the $625 million is cash, stock or earn-out, nor what regulatory approvals are required. The discrepancy in expected closing dates, before the end of the year per The Verge and before the end of 2027 per TechCrunch, is unresolved in the supplied reporting and should be treated as uncertain. It is also unclear how physician capacity scales: a network of about 50 doctors supporting a membership base that generates $1.75 billion in annual revenue implies either heavy triage by AI or significant hiring ahead. Clinical liability and data governance are the substantive risks. Counsel's model depends on physicians remaining in the loop for clinical decisions, as Alagappan described. As the service expands into chronic and specialty care, the boundary between advice and treatment will be tested, and the enterprise partners named by The Verge, including health plans and health systems, will hold Oura to their own compliance standards.

FY Outlook

The deal is best read as a bet that the durable advantage in consumer health wearables is not the sensor but the pathway from data to care. Oura is trading some of its balance-sheet flexibility, at a moment when it has chosen not to list, for a clinical capability it would take years to build. Watch three things: whether the closing date slips beyond the end of the year, how quickly Counsel's physician network grows beyond about 50, and whether enterprise partners outside Oura's membership renew on expanded terms. If those hold, the acquisition gives Oura a defensible position that ring hardware alone cannot. If physician capacity or regulatory friction bites, the $625 million will look expensive relative to Counsel's $36 million of prior funding.

Sources and References

• TechCrunch (techcrunch.com)
• The Verge (theverge.com)

Why It Matters

The deal marks a consumer wearable company buying clinical capacity rather than building it, and it sets a visible price for AI health assets that pair physician oversight with distribution. For founders and investors in regulated health AI, it is a concrete comparable: roughly $36 million of prior funding and a physician network of about 50 translated into a $625 million strategic valuation. It also shows Oura choosing acquisition over a postponed listing, which signals how privately held health hardware firms may fund expansion when public markets are uncertain.